View in EDS

Three‐day lansoprazole quadruple therapy for Helicobacter pylori‐positive duodenal ulcers: a randomized controlled study

Saved in:
Bibliographic Details
Title: Three‐day lansoprazole quadruple therapy for Helicobacter pylori‐positive duodenal ulcers: a randomized controlled study
Authors: W. H. Wang, B. C. Y. Wong, Kam Chuen Lai, Wai Man Wong, F. L. Hu, George K. K. Lau, Whc Hu, X. G. Liu, Nelson N.S. Kung, Kent-Man Chu, Wai Mo Hui, C. K. Chan, F. M. Y. Fung, MF Yuen, S. K. Lam
Source: Alimentary Pharmacology & Therapeutics. 15:843-849
Publisher Information: Wiley, 2001.
Publication Year: 2001
Subject Terms: Oral, Adult, Male, Adolescent, Duodenal Ulcer - drug therapy - microbiology - pathology, Administration, Oral, Medical sciences, Clarithromycin - administration & dosage - therapeutic use, 2-Pyridinylmethylsulfinylbenzimidazoles, Drug Administration Schedule, Anti-Infective Agents - administration & dosage - adverse effects - pharmacology, 03 medical and health sciences, 0302 clinical medicine, Drug Therapy, Anti-Infective Agents, Clarithromycin, Metronidazole, Organometallic Compounds, Humans, Lansoprazole, Organometallic Compounds - therapeutic use, Aged, Antacids - administration & dosage - therapeutic use, Metronidazole - administration & dosage - therapeutic use, Anti-Bacterial Agents - administration & dosage - therapeutic use, Middle Aged, Omeprazole - administration & dosage - adverse effects - analogs & derivatives - pharmacology, 3. Good health, Anti-Bacterial Agents, Treatment Outcome, Duodenal Ulcer, Combination, Administration, Drug Therapy, Combination, Female, Antacids, Omeprazole
Description: Aim:To compare the efficacy and tolerability of a 3‐day quadruple therapy with a standard 7‐day triple therapy in eradicating Helicobacter pylori infection and healing duodenal ulcers.Methods:Patients with H. pylori‐positive duodenal ulcers were randomized to receive either lansoprazole 30 mg, clarithromycin 500 mg, and metronidazole 400 mg twice daily for 7 days (LCM‐7) or lansoprazole 30 mg, clarithromycin 500 mg, metronidazole 400 mg, and bismuth subcitrate 240 mg twice daily for 3 days (LCMB‐3). No pre‐ or post‐treatment acid suppression was used. Follow‐up endoscopy was performed at week 6.Results:A total of 118 patients were recruited. Sixty patients in the LCM‐7 group and 53 patients in the LCMB‐3 group returned for endoscopy. Intention‐to‐treat eradication rates were 87% and 86% (P=0.94) and per protocol eradication rates were 87% and 94% (P=0.29) in the LCM‐7 and LCMB‐3 groups, respectively. Per protocol and intention‐to‐treat ulcer healing rates were 98% and 98% in LCM‐7 and 100% and 91% in LCMB‐3, respectively. There were no significant differences in efficacy in relation to the initial metronidazole and clarithromycin susceptibility. Significant reduction in the duration of side‐effects was found in the LCMB‐3 group.Conclusion:The 3‐day quadruple therapy is highly effective, better tolerated and can be considered as a first‐line therapy in duodenal ulcer management.
Document Type: Article
Conference object
File Description: 5131 bytes; 93869 bytes; 3198304 bytes; 9342 bytes; 3250 bytes; application/pdf; text/plain
Language: English
ISSN: 1365-2036
0269-2813
DOI: 10.1046/j.1365-2036.2001.00999.x
Access URL: https://onlinelibrary.wiley.com/doi/pdfdirect/10.1046/j.1365-2036.2001.00999.x
https://pubmed.ncbi.nlm.nih.gov/11380322
http://europepmc.org/abstract/MED/11380322
https://core.ac.uk/display/37909014
https://hub.hku.hk/handle/10722/78620
https://onlinelibrary.wiley.com/doi/10.1046/j.1365-2036.2001.00999.x
https://www.ncbi.nlm.nih.gov/pubmed/11380322
http://hdl.handle.net/10722/78422
http://hdl.handle.net/10722/46865
Rights: Wiley Online Library User Agreement
Accession Number: edsair.doi.dedup.....65f0c11f854923458f77bc7513f5355a
Database: OpenAIRE
Description
Abstract:Aim:To compare the efficacy and tolerability of a 3‐day quadruple therapy with a standard 7‐day triple therapy in eradicating Helicobacter pylori infection and healing duodenal ulcers.Methods:Patients with H. pylori‐positive duodenal ulcers were randomized to receive either lansoprazole 30 mg, clarithromycin 500 mg, and metronidazole 400 mg twice daily for 7 days (LCM‐7) or lansoprazole 30 mg, clarithromycin 500 mg, metronidazole 400 mg, and bismuth subcitrate 240 mg twice daily for 3 days (LCMB‐3). No pre‐ or post‐treatment acid suppression was used. Follow‐up endoscopy was performed at week 6.Results:A total of 118 patients were recruited. Sixty patients in the LCM‐7 group and 53 patients in the LCMB‐3 group returned for endoscopy. Intention‐to‐treat eradication rates were 87% and 86% (P=0.94) and per protocol eradication rates were 87% and 94% (P=0.29) in the LCM‐7 and LCMB‐3 groups, respectively. Per protocol and intention‐to‐treat ulcer healing rates were 98% and 98% in LCM‐7 and 100% and 91% in LCMB‐3, respectively. There were no significant differences in efficacy in relation to the initial metronidazole and clarithromycin susceptibility. Significant reduction in the duration of side‐effects was found in the LCMB‐3 group.Conclusion:The 3‐day quadruple therapy is highly effective, better tolerated and can be considered as a first‐line therapy in duodenal ulcer management.
ISSN:13652036
02692813
DOI:10.1046/j.1365-2036.2001.00999.x